estriol has been researched along with Atrophy in 73 studies
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone
chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "005% estriol vaginal gel showed efficacy in improving the symptoms and signs of vulvovaginal atrophy." | 9.34 | Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-contr ( Campos-Delgado, M; Gil-Gil, M; Hirschberg, AL; Lidbrink, E; Nieto-Magro, C; Presa-Lorite, J; Sánchez-Rovira, P; Suárez-Almarza, J, 2020) |
| "The aim of the study was to evaluate efficacy of fractional CO2 vaginal laser treatment (Laser, L) and compare it to local estrogen therapy (Estriol, E) and the combination of both treatments (Laser + Estriol, LE) in the treatment of vulvovaginal atrophy (VVA)." | 9.27 | Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. ( Cruz, VL; Fernandes, CE; Fonseca, FLA; Pompei, LM; Santiago, LHS; Steiner, ML; Strufaldi, R; Wajsfeld, T, 2018) |
| "005% estriol gel to the vulvar vestibule is effective in correcting menopausal coital pain." | 9.22 | Coital pain in the elderly: could a low dose estriol gel thrill the vulvar vestibule? ( Di Francesco, S; Felice, R; Graziottin, A; Murina, F, 2016) |
| " acidophili, estriol plus pelvic floor rehabilitation was effective and should be considered as first-line treatment for symptoms of urogenital aging in postmenopausal women." | 9.19 | Triple therapy with Lactobacilli acidophili, estriol plus pelvic floor rehabilitation for symptoms of urogenital aging in postmenopausal women. ( Capobianco, G; Cherchi, PL; Dessole, M; Dessole, S; Meloni, GB; Wenger, JM, 2014) |
| "03 mg estriol-lactobacilli combination (Gynoflor(®)) was superior to placebo with respect to changes in VMI after the 12-day initial therapy, and the maintenance therapy of two tablets weekly was sufficient to prevent the relapse of vaginal atrophy." | 9.17 | Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy. ( Chaikittisilpa, S; Grob, P; Jaisamrarn, U; Prasauskas, V; Taechakraichana, N; Triratanachat, S, 2013) |
| "005% Estriol vaginal gel, a new formulation providing an ultra low dose of estriol per application, was shown to be safe and effective in the treatment of postmenopausal vaginal atrophy." | 9.16 | The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. ( Cano, A; Castellanos, E; del Prado, JM; Delgado, JL; Estévez, J; Ferrer, J; Gallo, JL; Guinot, M; Moral, E; Nieto, C; Usandizaga, R, 2012) |
| "Superiority of estriol containing pessaries over placebo was shown in the local treatment of vaginal atrophy." | 9.16 | Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. ( Fielder, K; Fischer, T; Griesser, H; Skonietzki, S; Suesskind, M, 2012) |
| "To assess the effects of the combination of pelvic floor rehabilitation and intravaginal estriol administration on stress urinary incontinence (SUI), urogenital atrophy and recurrent urinary tract infections in postmenopausal women." | 9.16 | Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. ( Borghero, G; Capobianco, G; Cherchi, PL; Dessole, F; Dessole, S; Donolo, E, 2012) |
| "Improvement of acne scars was observed in 93% of patients treated with tretinoin iontophoresis and in 100% of the group treated with estriol iontophoresis." | 9.08 | New treatment of atrophic acne scars by iontophoresis with estriol and tretinoin. ( Bieglmayer, C; Binder, M; Macheiner, W; Schmidt, JB, 1995) |
| " One hundred and sixty five postmenopausal women with symptoms of vaginal dryness and signs of vaginal atrophy were randomized to an estradiol ring (Estring) or estriol cream (Synapause)." | 9.08 | Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. ( Barentsen, R; Schram, JH; van de Weijer, PH, 1997) |
| "To evaluate the efficacy and safety of estriol for the treatment of vulvovaginal atrophy in postmenopausal women." | 8.95 | The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. ( Avellaneda, AC; Osorio, AM; Pinzón, CE; Restrepo, OI; Rueda, C, 2017) |
| " Estriol is the main estrogen that specifically addresses problems associated with estrogen deficiency: dyspareunia, dryness and itching in the vagina and lower genitourinary tract, urinary incontinence, moderate urinary incontinence, and recurrent vulvovaginitis and cystitis." | 8.12 | [The role of estriol in the treatment of atrophy of the mucous membrane of the lower genitourinary tract in postmenopausal women]. ( Andreeva, EN; Sheremetyeva, EV, 2022) |
| "We investigated the effect of a combination of vaginal ultra-low-dose estriol with lactobacilli on the sexual functioning domain of quality of life during the treatment of breast cancer survivors on an aromatase inhibitor with vaginal atrophy." | 7.81 | Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. ( Bellen, G; Buchholz, S; Donders, G; Grob, P; Lintermans, A; Mögele, M; Neven, P; Ortmann, O; Prasauskas, V, 2015) |
| "Intravaginal estriol 1 mg/day for a period of 21 days was efficient in improving urogenital atrophy, Pap smear parameters and colposcopic evaluation in postmenopausal women." | 7.77 | Efficacy of vaginal use of topical estriol in postmenopausal women with urogenital atrophy. ( Belfort, PN; Chuery, AC; de Moura, KF; Ribalta, JC; Sakano, C; Speck, NM, 2011) |
| "The paper reports the results of a study to assess the efficacy of an estriol-based cream (Colpogyn) in the topical treatment of postmenopausal vaginal atrophy." | 7.68 | [Postmenopausal vaginal atrophy and topical therapy with an estriol-based ointment (Colpogyn): authors' experience]. ( D'Antonio, GD; Mazzatenta, E; Oliva, FA; Saltarelli, E, 1991) |
| " Vaginal pH measurement, subjective symptoms, and objective signs assessment of VVA, endometrial thickness and adverse events (AE) were recorded." | 6.94 | Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment. ( Amar, ID; Cipolla, C; Ingravalle, F; Lanzone, A; Ricciardi, W; Scambia, G; Tagliaferri, V; Villa, P, 2020) |
| "03 mg E3 and Lactobacillus acidophilus vaginal tablets application in postmenopausal BC patients during AI treatment suffering from vaginal atrophy lead to small and transient increases in serum E3, but not E1 or E2, and therefore can be considered as safe and efficacious for treatment of atrophic vaginitis in BC patients taking NSAIs." | 6.79 | Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. ( Bellen, G; Buchholz, S; Donders, G; Grob, P; Lintermans, A; Moegele, M; Neven, P; Ortmann, O; Prasauskas, V, 2014) |
| "Estriol treatment initiated after disease onset decreased cerebral cortex atrophy." | 5.91 | Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol. ( Farkhondeh, V; Gao, JL; Herbig, PD; Itoh, N; Itoh, Y; MacKenzie-Graham, A; Meyer, CE; Ngo, KH; Nguyen, Q; Oberoi, MR; Padilla-Requerey, AA; Siddarth, P; Smith, AW; Voskuhl, RR, 2023) |
| " Adverse events and discomfort encountered during the procedure were also assessed." | 5.72 | Short-Term Efficacy and Safety of Non-Ablative Laser Treatment Alone or with Estriol or Moisturizers in Postmenopausal Women with Vulvovaginal Atrophy. ( Alvisi, S; Baldassarre, M; Lami, A; Lenzi, J; Mancini, I; Meriggiola, MC; Seracchioli, R, 2022) |
| "005% estriol vaginal gel showed efficacy in improving the symptoms and signs of vulvovaginal atrophy." | 5.34 | Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-contr ( Campos-Delgado, M; Gil-Gil, M; Hirschberg, AL; Lidbrink, E; Nieto-Magro, C; Presa-Lorite, J; Sánchez-Rovira, P; Suárez-Almarza, J, 2020) |
| "The aim of the study was to evaluate efficacy of fractional CO2 vaginal laser treatment (Laser, L) and compare it to local estrogen therapy (Estriol, E) and the combination of both treatments (Laser + Estriol, LE) in the treatment of vulvovaginal atrophy (VVA)." | 5.27 | Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. ( Cruz, VL; Fernandes, CE; Fonseca, FLA; Pompei, LM; Santiago, LHS; Steiner, ML; Strufaldi, R; Wajsfeld, T, 2018) |
| "005% estriol gel to the vulvar vestibule is effective in correcting menopausal coital pain." | 5.22 | Coital pain in the elderly: could a low dose estriol gel thrill the vulvar vestibule? ( Di Francesco, S; Felice, R; Graziottin, A; Murina, F, 2016) |
| "Estriol 20 and 50 μg/g formulations, while showing a comparable capacity for reversing vaginal atrophy, present a highly favorable safety profile, producing a very low systemic absorption of estriol and significantly lower than that of Ovestinon®." | 5.22 | Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women. ( Delgado, JL; Estevez, J; Loprete, L; Moscoso Del Prado, J; Nieto Magro, C; Radicioni, M, 2016) |
| "Our study showed that vaginal supplementation with estriol 50 μg/g gel or with hyaluronic acid could reduce the de novo dyspareunia related to COC." | 5.20 | A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive. ( Bogani, G; Braghiroli, A; Cromi, A; Di Dedda, MC; Ghezzi, F; Serati, M; Uccella, S, 2015) |
| " acidophili, estriol plus pelvic floor rehabilitation was effective and should be considered as first-line treatment for symptoms of urogenital aging in postmenopausal women." | 5.19 | Triple therapy with Lactobacilli acidophili, estriol plus pelvic floor rehabilitation for symptoms of urogenital aging in postmenopausal women. ( Capobianco, G; Cherchi, PL; Dessole, M; Dessole, S; Meloni, GB; Wenger, JM, 2014) |
| "03 mg estriol-lactobacilli combination (Gynoflor(®)) was superior to placebo with respect to changes in VMI after the 12-day initial therapy, and the maintenance therapy of two tablets weekly was sufficient to prevent the relapse of vaginal atrophy." | 5.17 | Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy. ( Chaikittisilpa, S; Grob, P; Jaisamrarn, U; Prasauskas, V; Taechakraichana, N; Triratanachat, S, 2013) |
| "Superiority of estriol containing pessaries over placebo was shown in the local treatment of vaginal atrophy." | 5.16 | Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. ( Fielder, K; Fischer, T; Griesser, H; Skonietzki, S; Suesskind, M, 2012) |
| "To assess the effects of the combination of pelvic floor rehabilitation and intravaginal estriol administration on stress urinary incontinence (SUI), urogenital atrophy and recurrent urinary tract infections in postmenopausal women." | 5.16 | Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. ( Borghero, G; Capobianco, G; Cherchi, PL; Dessole, F; Dessole, S; Donolo, E, 2012) |
| "005% Estriol vaginal gel, a new formulation providing an ultra low dose of estriol per application, was shown to be safe and effective in the treatment of postmenopausal vaginal atrophy." | 5.16 | The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. ( Cano, A; Castellanos, E; del Prado, JM; Delgado, JL; Estévez, J; Ferrer, J; Gallo, JL; Guinot, M; Moral, E; Nieto, C; Usandizaga, R, 2012) |
| "Improvement of acne scars was observed in 93% of patients treated with tretinoin iontophoresis and in 100% of the group treated with estriol iontophoresis." | 5.08 | New treatment of atrophic acne scars by iontophoresis with estriol and tretinoin. ( Bieglmayer, C; Binder, M; Macheiner, W; Schmidt, JB, 1995) |
| "An intervention trial using oral oestriol to treat urinary incontinence was performed in a number of patients taken from a representative sample of 562 women aged 75 yr." | 5.05 | Occurrence, nature and treatment of urinary incontinence in a 70-year-old female population. ( Jansson, I; Mellström, D; Samsioe, G; Svanborg, A, 1985) |
| "To evaluate the efficacy and safety of estriol for the treatment of vulvovaginal atrophy in postmenopausal women." | 4.95 | The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. ( Avellaneda, AC; Osorio, AM; Pinzón, CE; Restrepo, OI; Rueda, C, 2017) |
| " Estriol is the main estrogen that specifically addresses problems associated with estrogen deficiency: dyspareunia, dryness and itching in the vagina and lower genitourinary tract, urinary incontinence, moderate urinary incontinence, and recurrent vulvovaginitis and cystitis." | 4.12 | [The role of estriol in the treatment of atrophy of the mucous membrane of the lower genitourinary tract in postmenopausal women]. ( Andreeva, EN; Sheremetyeva, EV, 2022) |
| "We investigated the effect of a combination of vaginal ultra-low-dose estriol with lactobacilli on the sexual functioning domain of quality of life during the treatment of breast cancer survivors on an aromatase inhibitor with vaginal atrophy." | 3.81 | Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. ( Bellen, G; Buchholz, S; Donders, G; Grob, P; Lintermans, A; Mögele, M; Neven, P; Ortmann, O; Prasauskas, V, 2015) |
| "Intravaginal estriol 1 mg/day for a period of 21 days was efficient in improving urogenital atrophy, Pap smear parameters and colposcopic evaluation in postmenopausal women." | 3.77 | Efficacy of vaginal use of topical estriol in postmenopausal women with urogenital atrophy. ( Belfort, PN; Chuery, AC; de Moura, KF; Ribalta, JC; Sakano, C; Speck, NM, 2011) |
| "Estriol, which has little effect on the endometrium, has the potential to be highly useful for the treatment of atrophic vaginitis." | 3.71 | Short term oral estriol treatment restores normal premenopausal vaginal flora to elderly women. ( Okamura, H; Yoshimura, T, 2001) |
| "The endometrial effect of long-term vaginal oestriol (E3) therapy for urogenital atrophy was assessed in 23 post-menopausal women." | 3.68 | Endometrial morphology after 12 months of vaginal oestriol therapy in post-menopausal women. ( Capitanio, GL; Croce, S; Ferraiolo, A; Gerbaldo, D; Truini, M, 1991) |
| "The paper reports the results of a study to assess the efficacy of an estriol-based cream (Colpogyn) in the topical treatment of postmenopausal vaginal atrophy." | 3.68 | [Postmenopausal vaginal atrophy and topical therapy with an estriol-based ointment (Colpogyn): authors' experience]. ( D'Antonio, GD; Mazzatenta, E; Oliva, FA; Saltarelli, E, 1991) |
| "Although some well-defined conditions require a replacement oestrogen therapy, local trophic disorders associated with the decrease of oestriol concentrations after surgical castration or menopause are corrected in a very satisfactory way by local oestrogen therapy." | 3.66 | Clinical, cytological and biological study of the intra-vaginal administration of oestriol (Ortho-Gynest) in post-menopausal patients. ( Etienne, J; Lestienne, MC; Wesel, S, 1981) |
| "The maturation value (MV), cervical mucus parameters (ferning, Spinnbarkeit), oestrone (E1), oestradiol (E2), oestriol (E3), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), thyrotropin (TSH), growth hormone (GH), sex hormone binding globulin (SHBG), corticosteroid binding globulin (CBG) and thyroxin-binding globulin (TBG) were determined in 11 post-menopausal women presenting with vaginal atrophy prior to, and following, treatment with Ovestin vaginal cream containing 0." | 3.66 | Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol. ( Haspels, AA; Kicovic, PM; Luisi, M, 1981) |
| " Vaginal pH measurement, subjective symptoms, and objective signs assessment of VVA, endometrial thickness and adverse events (AE) were recorded." | 2.94 | Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment. ( Amar, ID; Cipolla, C; Ingravalle, F; Lanzone, A; Ricciardi, W; Scambia, G; Tagliaferri, V; Villa, P, 2020) |
| "03 mg E3 and Lactobacillus acidophilus vaginal tablets application in postmenopausal BC patients during AI treatment suffering from vaginal atrophy lead to small and transient increases in serum E3, but not E1 or E2, and therefore can be considered as safe and efficacious for treatment of atrophic vaginitis in BC patients taking NSAIs." | 2.79 | Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. ( Bellen, G; Buchholz, S; Donders, G; Grob, P; Lintermans, A; Moegele, M; Neven, P; Ortmann, O; Prasauskas, V, 2014) |
| " Vaginal estrogen products seem to be safe with few adverse effects, although there is a lack of long-term controlled clinical trial safety data." | 2.61 | A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. ( Biehl, C; Mirkin, S; Plotsker, O, 2019) |
| "Estriol treatment initiated after disease onset decreased cerebral cortex atrophy." | 1.91 | Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol. ( Farkhondeh, V; Gao, JL; Herbig, PD; Itoh, N; Itoh, Y; MacKenzie-Graham, A; Meyer, CE; Ngo, KH; Nguyen, Q; Oberoi, MR; Padilla-Requerey, AA; Siddarth, P; Smith, AW; Voskuhl, RR, 2023) |
| " Adverse events and discomfort encountered during the procedure were also assessed." | 1.72 | Short-Term Efficacy and Safety of Non-Ablative Laser Treatment Alone or with Estriol or Moisturizers in Postmenopausal Women with Vulvovaginal Atrophy. ( Alvisi, S; Baldassarre, M; Lami, A; Lenzi, J; Mancini, I; Meriggiola, MC; Seracchioli, R, 2022) |
| "The syndrome is underreported and undertreated in Norway." | 1.28 | [Urogenital estrogen deficiency syndrome. Investigation and treatment with special reference to hormone substitution]. ( Eriksen, BC; Hunskår, S, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (27.40) | 18.7374 |
| 1990's | 12 (16.44) | 18.2507 |
| 2000's | 5 (6.85) | 29.6817 |
| 2010's | 28 (38.36) | 24.3611 |
| 2020's | 8 (10.96) | 2.80 |
| Authors | Studies |
|---|---|
| Alvisi, S | 1 |
| Lami, A | 1 |
| Baldassarre, M | 1 |
| Lenzi, J | 1 |
| Mancini, I | 1 |
| Seracchioli, R | 1 |
| Meriggiola, MC | 1 |
| Garcia de Arriba, S | 1 |
| Grüntkemeier, L | 1 |
| Häuser, M | 1 |
| May, TW | 1 |
| Masur, C | 1 |
| Stute, P | 1 |
| Andreeva, EN | 1 |
| Sheremetyeva, EV | 1 |
| Donders, GGG | 2 |
| Donders, FHWV | 1 |
| Meyer, CE | 1 |
| Smith, AW | 1 |
| Padilla-Requerey, AA | 1 |
| Farkhondeh, V | 1 |
| Itoh, N | 1 |
| Itoh, Y | 2 |
| Gao, JL | 1 |
| Herbig, PD | 1 |
| Nguyen, Q | 1 |
| Ngo, KH | 1 |
| Oberoi, MR | 1 |
| Siddarth, P | 1 |
| Voskuhl, RR | 2 |
| MacKenzie-Graham, A | 2 |
| Comini, ACM | 1 |
| Carvalho, BM | 1 |
| Moreira, MJB | 1 |
| Reis, PCA | 1 |
| Colapietro, L | 1 |
| Northern, J | 1 |
| Batalini, F | 1 |
| Villa, P | 1 |
| Tagliaferri, V | 1 |
| Amar, ID | 1 |
| Cipolla, C | 1 |
| Ingravalle, F | 1 |
| Scambia, G | 1 |
| Ricciardi, W | 1 |
| Lanzone, A | 1 |
| Hirschberg, AL | 1 |
| Sánchez-Rovira, P | 1 |
| Presa-Lorite, J | 1 |
| Campos-Delgado, M | 1 |
| Gil-Gil, M | 1 |
| Lidbrink, E | 1 |
| Suárez-Almarza, J | 1 |
| Nieto-Magro, C | 1 |
| Caruso, S | 2 |
| Cianci, S | 2 |
| Vitale, SG | 1 |
| Matarazzo, MG | 1 |
| Amore, FF | 2 |
| Cianci, A | 2 |
| Rueda, C | 1 |
| Osorio, AM | 1 |
| Avellaneda, AC | 1 |
| Pinzón, CE | 1 |
| Restrepo, OI | 1 |
| Cruz, VL | 1 |
| Steiner, ML | 1 |
| Pompei, LM | 1 |
| Strufaldi, R | 1 |
| Fonseca, FLA | 1 |
| Santiago, LHS | 1 |
| Wajsfeld, T | 1 |
| Fernandes, CE | 1 |
| Mitchell, CM | 1 |
| Leone Roberti Maggiore, U | 1 |
| Ferrero, S | 1 |
| Mueck, AO | 1 |
| Ruan, X | 1 |
| Prasauskas, V | 4 |
| Grob, P | 4 |
| Ortmann, O | 3 |
| Maher, C | 1 |
| Buttini, M | 1 |
| Brook, J | 1 |
| Kurth, F | 1 |
| Meyer, C | 1 |
| Montag, MJ | 1 |
| Wang, HJ | 1 |
| Elashoff, R | 1 |
| Biehl, C | 1 |
| Plotsker, O | 1 |
| Mirkin, S | 1 |
| Ruban, K | 1 |
| Bellen, G | 3 |
| Grinceviciene, S | 1 |
| Capobianco, G | 2 |
| Wenger, JM | 1 |
| Meloni, GB | 1 |
| Dessole, M | 1 |
| Cherchi, PL | 2 |
| Dessole, S | 2 |
| Donders, G | 2 |
| Neven, P | 2 |
| Moegele, M | 1 |
| Lintermans, A | 2 |
| Buchholz, S | 2 |
| Mögele, M | 1 |
| Serati, M | 1 |
| Bogani, G | 1 |
| Di Dedda, MC | 1 |
| Braghiroli, A | 1 |
| Uccella, S | 1 |
| Cromi, A | 1 |
| Ghezzi, F | 1 |
| Ventura, B | 1 |
| Bambili, E | 1 |
| Spadola, S | 1 |
| Meaidi, A | 1 |
| Goukasian, I | 1 |
| Lidegaard, O | 1 |
| Delgado, JL | 3 |
| Estevez, J | 3 |
| Radicioni, M | 1 |
| Loprete, L | 1 |
| Moscoso Del Prado, J | 1 |
| Nieto Magro, C | 1 |
| Weber, MA | 1 |
| Lim, V | 1 |
| Oryszczyn, J | 1 |
| Te West, N | 1 |
| Souget, J | 1 |
| Jeffery, S | 1 |
| Roovers, JP | 1 |
| Moore, KH | 1 |
| Murina, F | 1 |
| Graziottin, A | 1 |
| Felice, R | 1 |
| Di Francesco, S | 1 |
| Biglia, N | 1 |
| Peano, E | 1 |
| Sgandurra, P | 1 |
| Moggio, G | 1 |
| Panuccio, E | 1 |
| Migliardi, M | 1 |
| Ravarino, N | 1 |
| Ponzone, R | 1 |
| Sismondi, P | 1 |
| Gray, S | 1 |
| Donolo, E | 1 |
| Borghero, G | 1 |
| Dessole, F | 1 |
| Chuery, AC | 1 |
| Speck, NM | 1 |
| de Moura, KF | 1 |
| Belfort, PN | 1 |
| Sakano, C | 1 |
| Ribalta, JC | 1 |
| Griesser, H | 1 |
| Skonietzki, S | 1 |
| Fischer, T | 1 |
| Fielder, K | 1 |
| Suesskind, M | 1 |
| López-Belmonte, J | 1 |
| Nieto, C | 2 |
| del Prado, JM | 2 |
| Cano, A | 1 |
| Usandizaga, R | 1 |
| Gallo, JL | 1 |
| Guinot, M | 1 |
| Castellanos, E | 1 |
| Moral, E | 1 |
| Ferrer, J | 1 |
| Mariani, L | 1 |
| Gadducci, A | 1 |
| Vizza, E | 1 |
| Tomao, S | 1 |
| Vici, P | 1 |
| Jaisamrarn, U | 1 |
| Triratanachat, S | 1 |
| Chaikittisilpa, S | 1 |
| Taechakraichana, N | 1 |
| Liu, H | 1 |
| Xu, K | 1 |
| Tan, J | 1 |
| Yang, S | 1 |
| CROOKE, AC | 1 |
| BUTT, WR | 1 |
| PALMER, RF | 1 |
| MORRIS, R | 1 |
| EDWARDS, RL | 1 |
| ANSON, CJ | 1 |
| Palacios, S | 1 |
| Castelo-Branco, C | 1 |
| Cancelo, MJ | 1 |
| Vázquez, F | 1 |
| Kicovic, PM | 2 |
| Cortes-Prieto, J | 1 |
| Milojević, S | 1 |
| Haspels, AA | 2 |
| Aljinovic, A | 1 |
| Luisi, M | 1 |
| Michalas, S | 1 |
| Papandrikos, A | 1 |
| Koutselini, E | 1 |
| Tzingounis, V | 1 |
| Wesel, S | 1 |
| Etienne, J | 1 |
| Lestienne, MC | 1 |
| Koloszár, S | 1 |
| Kovács, L | 1 |
| Schmidt, JB | 1 |
| Binder, M | 1 |
| Macheiner, W | 1 |
| Bieglmayer, C | 1 |
| Cabrera, J | 1 |
| Canahuate, E | 1 |
| del Campo, SL | 1 |
| Poloni, O | 1 |
| Ramírez, SI | 1 |
| Henriksson, L | 1 |
| Stjernquist, M | 1 |
| Boquist, L | 1 |
| Alander, U | 1 |
| Selinus, I | 1 |
| van der Linden, MC | 1 |
| Gerretsen, G | 1 |
| Brandhorst, MS | 1 |
| Ooms, EC | 1 |
| Kremer, CM | 1 |
| Doesburg, WH | 1 |
| Barentsen, R | 1 |
| van de Weijer, PH | 1 |
| Schram, JH | 1 |
| Dugal, R | 1 |
| Hesla, K | 1 |
| Sørdal, T | 1 |
| Aase, KH | 1 |
| Lilleeidet, O | 1 |
| Wickstrøm, E | 1 |
| Bulten, J | 1 |
| de Wilde, PC | 1 |
| Boonstra, H | 1 |
| Gemmink, JH | 1 |
| Hanselaar, AG | 1 |
| Yoshimura, T | 1 |
| Okamura, H | 1 |
| Hustin, J | 1 |
| Drykoningen, GJ | 1 |
| Karoussos, KE | 1 |
| Studer, S | 1 |
| Wyss, HJ | 1 |
| Ciaccio, LA | 1 |
| Joseph, AA | 1 |
| Kincl, FA | 1 |
| Purola, E | 1 |
| Vartiainen, E | 1 |
| Heimer, GM | 1 |
| Englund, DE | 1 |
| Iosif, CS | 1 |
| Gerbaldo, D | 1 |
| Ferraiolo, A | 1 |
| Croce, S | 1 |
| Truini, M | 1 |
| Capitanio, GL | 1 |
| Oliva, FA | 1 |
| Saltarelli, E | 1 |
| D'Antonio, GD | 1 |
| Mazzatenta, E | 1 |
| Eriksen, BC | 1 |
| Hunskår, S | 1 |
| Tolino, A | 1 |
| Ronsini, S | 1 |
| Granata, P | 1 |
| Gallo, FP | 1 |
| Riccio, S | 1 |
| Montemagno, U | 1 |
| Staland, B | 1 |
| Samsioe, G | 1 |
| Jansson, I | 1 |
| Mellström, D | 1 |
| Svanborg, A | 1 |
| Fischer, W | 1 |
| Hannig, I | 1 |
| Lieveaux, A | 1 |
| Weniger, JP | 1 |
| Aertgeerts, J | 1 |
| Bachmann, FF | 1 |
| Punnonen, R | 2 |
| Rauramo, L | 1 |
| Procopé, BJ | 1 |
| Adlercreutz, H | 1 |
| Lauritzen, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Laser Therapy on Vaginal Tissue at Biomechanical, Histological and Molecular Level in Women With Pelvic Organ Prolapse - Pilot Study[NCT05898191] | 15 participants (Actual) | Interventional | 2019-02-01 | Active, not recruiting | |||
| A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.[NCT01466114] | Phase 2 | 64 participants (Anticipated) | Interventional | 2011-10-31 | Recruiting | ||
| Effects on Vaginal Health and Quality of Life in Postmenopausal Women Using Ultra Low Topic Estriol Before Vaginal Surgery for Pelvic Statics Disorders[NCT02906111] | Phase 4 | 88 participants (Anticipated) | Interventional | 2016-11-30 | Not yet recruiting | ||
| Prospective, Open-label, Multicenter, Multinational, Randomized Trial to Investigate the Non-inferiority of Treatment With WO2085 Moisturising Cream in Comparison to a Cream With 0.1% Estriol in a Panel of Post-menopausal Women Suffering From the Symptoms[NCT03044652] | Phase 4 | 172 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicentre Study, to Determine Efficacy and Safety of a Low Concentration Estriol (ITFE-2026 0.005%) by Vaginal Route in the Treatment of Postmenopausal Vaginal Atrophy.[NCT04574999] | Phase 3 | 167 participants (Actual) | Interventional | 2008-01-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Maturation value (MV) is a cytologic parameter indicative of the degree of atrophy of the vaginal mucosa.~This variable is a quantitative parameter indicative of the cytological status of the vaginal epithelium. The number of parabasal, intermediate and superficial cells was calculated from 300 consecutive cells of the samples of vaginal cytology, and the percentages of each type of cells obtained. The Maturation Value was obtained based on the following formula: 0.2 x (% parabasal) + 0.6 x (% intermediate) + 1.0 x (% superficial). The higher the value, the higher the maturation degree." (NCT04574999)
Timeframe: At week 12/Early withdrawal
| Intervention | vaginal health index (Mean) |
|---|---|
| 0.005% Estriol Group | 26.9 |
| Placebo Group | 3.2 |
As a consequence of reduced estrogen levels, the vaginal mucosa occurs loses its rugosity, its thickness decreases, and it becomes pale and friable. The production of glycogen decreases, which determines vaginal pH alkalinization. (NCT04574999)
Timeframe: At week 12 /early withdrawal
| Intervention | pH units (Mean) |
|---|---|
| 0.005% Estriol Group | -1.2 |
| Placebo Group | -0.4 |
"Maturation value (MV) is a cytologic parameter indicative of the degree of atrophy of the vaginal mucosa.~This variable is a quantitative parameter indicative of the cytological status of the vaginal epithelium. The number of parabasal, intermediate and superficial cells was calculated from 300 consecutive cells of the samples of vaginal cytology, and the percentages of each type of cells obtained. The Maturation Value was obtained based on the following formula: 0.2 x (% parabasal) + 0.6 x (% intermediate) + 1.0 x (% superficial). The higher the value, the higher the maturation degree." (NCT04574999)
Timeframe: At week 3/ early withdrawal
| Intervention | vaginal health index (Mean) |
|---|---|
| 0.005% Estriol Group | 37.9 |
| Placebo Group | 3.6 |
As a consequence of reduced estrogen levels, the vaginal mucosa occurs loses its rugosity, its thickness decreases, and it becomes pale and friable. The production of glycogen decreases, which determines vaginal pH alkalinization. (NCT04574999)
Timeframe: At week 3 / early withdrawal
| Intervention | pH units (Mean) |
|---|---|
| 0.005% Estriol Group | -1.4 |
| Placebo Group | -0.3 |
"Signs and symptoms of vaginal atrophy are: vaginal dryness, pruritus or itching, burning, dyspareunia, dysuria.~For each of these symptoms the subject indicates one the following status: present, absent, missing.~Symptoms of vaginal atrophy were scored by the patients in a numeric scale from 0 to 3, as shown below:~0 Absence. The symptom is not present~The symptom is of mild intensity, without interfering in the patient's activity~The symptom is of moderate intensity, causing obvious discomfort to the patient's~The symptom is very irritating and severe in intensity~Signs of vaginal atrophy were evaluated by the investigator and scored on a numerical scale as shown below:~0 Absence. The symptom is not present~The sign is present and is considered a mild alteration~The sign is present and is considered a moderate alteration~The sign is present and is considered a severe alteration" (NCT04574999)
Timeframe: At baseline and at 12 weeks / early withdrawal
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaginal dryness - Baseline - present | Vaginal dryness - Baseline - absent | Vaginal dryness - Baseline - missing | Vaginal dryness - week 12 - present | Vaginal dryness - week 12 - absent | Vaginal dryness - week 12 - missing | Pruritus - Baseline - present | Pruritus - Baseline - absent | Pruritus - Baseline - missing | Pruritus - week 12 - present | Pruritus - week 12 - absent | Pruritus - week 12 - missing | Burning - Baseline - present | Burning - Baseline - absent | Burning - Baseline - missing | Burning - week 12 - present | Burning - week 12 - absent | Burning - week 12 - missing | Dyspareunia - Baseline - present | Dyspareunia - Baseline - absent | Dyspareunia - Baseline - missing | Dyspareunia - week 12 - present | Dyspareunia - week 12 - absent | Dyspareunia - week 12 - missing | Dysuria - Baseline - present | Dysuria - Baseline - absent | Dysuria - Baseline - missing | Dysuria - week 12 - present | Dysuria - week 12 - absent | Dysuria - week 12 - missing | |
| 0.005% Estriol Group | 114 | 0 | 0 | 71 | 39 | 3 | 55 | 59 | 0 | 18 | 92 | 3 | 48 | 66 | 0 | 14 | 96 | 3 | 101 | 11 | 2 | 51 | 56 | 6 | 27 | 85 | 2 | 2 | 108 | 3 |
| Placebo Group | 53 | 0 | 0 | 39 | 12 | 2 | 29 | 24 | 0 | 11 | 40 | 2 | 18 | 35 | 0 | 11 | 40 | 2 | 48 | 5 | 0 | 24 | 25 | 4 | 14 | 39 | 0 | 7 | 44 | 2 |
"Signs and symptoms of vaginal atrophy are: vaginal dryness, pruritus or itching, burning, dyspareunia, dysuria.~For each of these symptoms the subject indicates one the following status: present, absent, missing.~Symptoms of vaginal atrophy were scored by the patients in a numeric scale from 0 to 3, as shown below:~0 Absence. The symptom is not present~The symptom is of mild intensity, without interfering in the patient's activity~The symptom is of moderate intensity, causing obvious discomfort to the patient's~The symptom is very irritating and severe in intensity~Signs of vaginal atrophy were evaluated by the investigator and scored on a numerical scale as shown below:~0 Absence. The symptom is not present~The sign is present and is considered a mild alteration~The sign is present and is considered a moderate alteration~The sign is present and is considered a severe alteration" (NCT04574999)
Timeframe: At 3 weeks
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaginal dryness - Baseline - present | Vaginal dryness - Baseline - absent | Vaginal dryness - Baseline - missing | Vaginal dryness - week 3 - present | Vaginal dryness - week 3 - absent | Vaginal dryness - week 3 - missing | Pruritus - Baseline - present | Pruritus - Baseline - absent | Pruritus - Baseline - missing | Pruritus - week 3 - present | Pruritus - week 3 - absent | Pruritus - week 3 - missing | Burning - Baseline - present | Burning - Baseline - absent | Burning - Baseline - missing | Burning - week 3 - present | Burning - week 3 - absent | Burning - week 3 - missing | Dyspareunia - Baseline - present | Dyspareunia - Baseline - absent | Dyspareunia - Baseline - missing | Dyspareunia - week 3 - present | Dyspareunia - week 3 - absent | Dyspareunia - week 3 - missing | Dysuria - Baseline - present | Dysuria - Baseline - absent | Dysuria - Baseline - missing | Dysuria - week 3 - present | Dysuria - week 3 - absent | Dysuria - week 3 - missing | |
| 0.005% Estriol Group | 114 | 0 | 0 | 84 | 21 | 0 | 55 | 59 | 0 | 21 | 84 | 0 | 48 | 66 | 0 | 22 | 83 | 0 | 101 | 11 | 2 | 60 | 40 | 5 | 27 | 85 | 2 | 7 | 98 | 0 |
| Placebo Group | 53 | 0 | 0 | 43 | 8 | 0 | 29 | 24 | 0 | 13 | 38 | 0 | 18 | 35 | 0 | 11 | 40 | 0 | 48 | 5 | 0 | 32 | 16 | 3 | 14 | 39 | 0 | 5 | 46 | 0 |
6 reviews available for estriol and Atrophy
| Article | Year |
|---|---|
New developments in the management of vulvovaginal atrophy: a comprehensive overview.
Topics: Atrophy; Estriol; Estrogens; Female; Humans; Selective Estrogen Receptor Modulators; Vagina; Vaginal | 2023 |
Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Topics: Atrophy; Breast Neoplasms; Cancer Survivors; Estradiol; Estriol; Estrogens; Female; Humans; Neoplasm | 2023 |
The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review.
Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Endometrium; Estriol; Female; | 2017 |
Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review.
Topics: Administration, Intravaginal; Atrophy; Combined Modality Therapy; Estriol; Female; Humans; Lactobaci | 2018 |
A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Atrophy; Estriol; Estrogen Replacement Therapy; Estrogens; Female; Hum | 2019 |
Pharmacotherapy for the treatment of vaginal atrophy.
Topics: Atrophy; Estradiol; Estriol; Female; Humans; Probiotics; Progestins; Receptors, Estrogen; Vagina; Vi | 2019 |
25 trials available for estriol and Atrophy
| Article | Year |
|---|---|
Vaginal hormone-free moisturising cream is not inferior to an estriol cream for treating symptoms of vulvovaginal atrophy: Prospective, randomised study.
Topics: Administration, Intravaginal; Atrophy; Dyspareunia; Estriol; Female; Humans; Male; Postmenopause; Pr | 2022 |
Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment.
Topics: Administration, Topical; Adult; Aged; Atrophy; Dose-Response Relationship, Drug; Drug Administration | 2020 |
Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-contr
Topics: Administration, Intravaginal; Aromatase Inhibitors; Atrophy; Breast Neoplasms; Estriol; Estrogens; F | 2020 |
Effects of ultralow topical estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse.
Topics: Atrophy; Estriol; Female; Humans; Interviews as Topic; Middle Aged; Pelvic Organ Prolapse; Postmenop | 2017 |
Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women.
Topics: Administration, Intravaginal; Aged; Atrophy; Double-Blind Method; Estriol; Female; Humans; Lasers, G | 2018 |
Triple therapy with Lactobacilli acidophili, estriol plus pelvic floor rehabilitation for symptoms of urogenital aging in postmenopausal women.
Topics: Administration, Intravaginal; Aged; Aging; Atrophy; Combined Modality Therapy; Electric Stimulation | 2014 |
Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study.
Topics: Administration, Intravaginal; Aromatase Inhibitors; Atrophy; Breast Neoplasms; Estradiol; Estriol; F | 2014 |
A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive.
Topics: Adult; Atrophy; Contraceptives, Oral, Hormonal; Drug Administration Schedule; Dyspareunia; Estriol; | 2015 |
Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women.
Topics: Administration, Intravaginal; Aged; Atrophy; Biological Availability; Estriol; Female; Gels; Humans; | 2016 |
Coital pain in the elderly: could a low dose estriol gel thrill the vulvar vestibule?
Topics: Aged; Aging; Atrophy; Drug Administration Schedule; Dyspareunia; Estriol; Estrogens; Female; Gels; H | 2016 |
Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women.
Topics: Administration, Intravaginal; Aging; Analysis of Variance; Atrophy; Dyspareunia; Electric Stimulatio | 2012 |
Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol.
Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Double-Blind Method; Estriol; | 2012 |
The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study.
Topics: Atrophy; Double-Blind Method; Estriol; Estrogens; Female; Humans; Hydrogen-Ion Concentration; Middle | 2012 |
Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy.
Topics: Administration, Intravaginal; Atrophy; Double-Blind Method; Epithelium; Estriol; Female; Humans; Lac | 2013 |
Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
Topics: Administration, Cutaneous; Administration, Intravaginal; Adult; Atrophy; Colposcopy; Contraceptive A | 2005 |
Local therapy of atrophic vaginal conditions with oestriol suppositories.
Topics: Aged; Atrophy; Clinical Trials as Topic; Estriol; Female; Humans; Menopause; Middle Aged; Suppositor | 1980 |
New treatment of atrophic acne scars by iontophoresis with estriol and tretinoin.
Topics: Acne Vulgaris; Administration, Cutaneous; Adult; Atrophy; Cicatrix; Drug Eruptions; Estradiol; Estri | 1995 |
A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy.
Topics: Administration, Intravaginal; Aged; Atrophy; Contraceptive Devices, Female; Delayed-Action Preparati | 1994 |
The effect of estriol on the cytology of urethra and vagina in postmenopausal women with genito-urinary symptoms.
Topics: Aged; Atrophy; Double-Blind Method; Epithelium; Estriol; Estrogen Replacement Therapy; Female; Human | 1993 |
Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy.
Topics: Administration, Intravaginal; Atrophy; Cross-Over Studies; Estradiol; Estriol; Female; Humans; Hydro | 1997 |
Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy.
Topics: Administration, Intravaginal; Aged; Atrophy; Drug Administration Schedule; Estradiol; Estriol; Femal | 2000 |
Effects of vaginally-administered oestriol on post-menopausal urogenital disorders: a cytohormonal study.
Topics: Administration, Intravaginal; Aged; Aged, 80 and over; Atrophy; Bacteriuria; Epithelium; Estriol; Fe | 1992 |
[Topical treatment with estriol in postmenopausal atrophic vaginitis].
Topics: Aged; Aged, 80 and over; Atrophy; Colposcopy; Double-Blind Method; Estriol; Female; Follicle Stimula | 1990 |
Occurrence, nature and treatment of urinary incontinence in a 70-year-old female population.
Topics: Aged; Atrophy; Clinical Trials as Topic; Double-Blind Method; Epidemiologic Methods; Estriol; Female | 1985 |
[Experience with an injectionable estriol Depot preparation. (Gynaesan pro injectione)].
Topics: Atrophy; Estriol; Female; Genital Diseases, Female; Humans; Injections, Intramuscular; Leukoplakia; | 1968 |
42 other studies available for estriol and Atrophy
| Article | Year |
|---|---|
Short-Term Efficacy and Safety of Non-Ablative Laser Treatment Alone or with Estriol or Moisturizers in Postmenopausal Women with Vulvovaginal Atrophy.
Topics: Atrophy; Carbon Dioxide; Estriol; Female; Humans; Pain; Postmenopause; Pruritus; Quality of Life; Tr | 2022 |
[The role of estriol in the treatment of atrophy of the mucous membrane of the lower genitourinary tract in postmenopausal women].
Topics: Aged; Atrophy; Estriol; Estrogens; Female; Humans; Mucous Membrane; Postmenopause; Urinary Incontine | 2022 |
Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol.
Topics: Animals; Atrophy; Cerebral Cortex; Encephalomyelitis, Autoimmune, Experimental; Estriol; Female; Mic | 2023 |
Seeing the light: the need for randomized trials of vaginal laser in postmenopausal women.
Topics: Atrophy; Double-Blind Method; Estriol; Female; Humans; Lasers, Gas; Postmenopause; Randomized Contro | 2018 |
To the Editor.
Topics: Atrophy; Double-Blind Method; Estriol; Female; Humans; Lasers, Gas; Postmenopause | 2018 |
To the Editor.
Topics: Atrophy; Double-Blind Method; Estriol; Female; Humans; Lasers, Gas; Postmenopause | 2018 |
Estriol-mediated neuroprotection in multiple sclerosis localized by voxel-based morphometry.
Topics: Adult; Atrophy; Cognitive Dysfunction; Estriol; Female; Gray Matter; Humans; Magnetic Resonance Imag | 2018 |
Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer.
Topics: Administration, Intravaginal; Aromatase Inhibitors; Atrophy; Breast Neoplasms; Combined Modality The | 2015 |
Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel.
Topics: Administration, Intravaginal; Atrophy; Case-Control Studies; Estriol; Female; Humans; Middle Aged; P | 2016 |
Use of vaginal estrogen in Danish women: a nationwide cross-sectional study.
Topics: Administration, Intravaginal; Adult; Age Factors; Aged; Atrophy; Cross-Sectional Studies; Denmark; D | 2016 |
The Effect of Vaginal Oestriol Cream on Subjective and Objective Symptoms of Stress Urinary Incontinence and Vaginal Atrophy: An International Multi-Centre Pilot Study.
Topics: Administration, Intravaginal; Aged; Atrophy; Estriol; Female; Humans; Hydrogen-Ion Concentration; Mi | 2017 |
Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study.
Topics: Acrylic Resins; Administration, Intravaginal; Atrophy; Breast Neoplasms; Estradiol; Estriol; Estroge | 2010 |
Practice observed.
Topics: Atrophy; Estradiol; Estriol; Female; Hormone Replacement Therapy; Humans; Middle Aged; Perimenopause | 2010 |
Efficacy of vaginal use of topical estriol in postmenopausal women with urogenital atrophy.
Topics: Administration, Intravaginal; Aged; Atrophy; Estriol; Female; Female Urogenital Diseases; Humans; Mi | 2011 |
Comparative uterine effects on ovariectomized rats after repeated treatment with different vaginal estrogen formulations.
Topics: Administration, Intravaginal; Animals; Atrophy; Endometrium; Estradiol; Estriol; Estrogens; Female; | 2012 |
Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy.
Topics: Administration, Intravaginal; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Atrophy; Breast | 2013 |
[Effects of Nilestriol on reproductive system in ovariectomized rats].
Topics: Animals; Atrophy; Endometrium; Estriol; Female; Organ Size; Ovariectomy; Quinestrol; Random Allocati | 2000 |
CLINICAL TRIAL OF HUMAN GONADOTROPHINS. I. THE EFFECT OF PITUITARY AND URINARY FOLLICLE STIMULATING HORMONE AND CHORIONIC GONADOTROPHIN ON PATIENTS WITH IDIOPATHIC SECONDARY AMENORRHOEA.
Topics: Amenorrhea; Atrophy; Chorionic Gonadotropin; Estriol; Factor Analysis, Statistical; Female; Follicle | 1963 |
The treatment of postmenopausal vaginal atrophy with Ovestin vaginal cream or suppositories: clinical, endocrinological and safety aspects.
Topics: Adult; Aged; Atrophy; Biopsy; Cervix Mucus; Endometrium; Estriol; Female; Follicle Stimulating Hormo | 1980 |
Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol.
Topics: Administration, Topical; Aged; Atrophy; Cervix Mucus; Estriol; Estrogens; Female; Humans; Menopause; | 1981 |
Clinical, cytological and biological study of the intra-vaginal administration of oestriol (Ortho-Gynest) in post-menopausal patients.
Topics: Administration, Topical; Adult; Aged; Atrophy; Castration; Climacteric; Estradiol; Estriol; Female; | 1981 |
[Treatment of climacteric urogenital disorders with an estriol-containing ointment].
Topics: Administration, Topical; Aged; Aged, 80 and over; Atrophy; Cystitis; Epithelium; Estriol; Female; Fe | 1995 |
[Cytologic response of the irradiated vagina to estriol succinate].
Topics: Adult; Atrophy; Estriol; Female; Humans; Libido; Middle Aged; Prospective Studies; Radiation Injurie | 1993 |
Proliferation in "atypical" atrophic pap smears.
Topics: Antibodies, Monoclonal; Atrophy; Cell Division; Cervix Uteri; Decision Trees; Diagnosis, Differentia | 2000 |
Short term oral estriol treatment restores normal premenopausal vaginal flora to elderly women.
Topics: Administration, Oral; Aged; Atrophy; Endometrium; Estriol; Female; Humans; Lactobacillus; Middle Age | 2001 |
Estrogen treatment of postmenopausal vaginal atrophy--a cytological assessment.
Topics: Adult; Aged; Atrophy; Biopsy, Needle; Endometrium; Estriol; Estrogens; Female; Humans; Middle Aged; | 1979 |
The treatment of atrophic vaginal conditions with Ortho-Gynest: a pilot study.
Topics: Aged; Atrophy; Estriol; Female; Humans; Middle Aged; Suppositories; Vagina | 1979 |
Direct inhibition of testicular function in rats by estriol and progesterone.
Topics: Androstenedione; Animals; Atrophy; Body Weight; Dihydrotestosterone; Estriol; Male; Organ Size; Prog | 1978 |
Effect of long-acting oestriol on the vaginal cytology of postmenopausal women.
Topics: Atrophy; Estriol; Female; Humans; Injections, Intramuscular; Menopause; Middle Aged; Time Factors; V | 1977 |
Effects of protracted administration of estriol on the lower genito urinary tract in postmenopausal women.
Topics: Administration, Intravaginal; Aged; Atrophy; Estriol; Estrogen Replacement Therapy; Female; Humans; | 1992 |
Endometrial morphology after 12 months of vaginal oestriol therapy in post-menopausal women.
Topics: Administration, Intravaginal; Atrophy; Endometrium; Estriol; Female; Humans; Hysteroscopy; Menopause | 1991 |
[Postmenopausal vaginal atrophy and topical therapy with an estriol-based ointment (Colpogyn): authors' experience].
Topics: Adult; Aged; Atrophy; Estriol; Female; Humans; Menopause; Middle Aged; Vagina; Vaginal Creams, Foams | 1991 |
[Urogenital estrogen deficiency syndrome. Investigation and treatment with special reference to hormone substitution].
Topics: Aged; Atrophy; Estriol; Estrogen Replacement Therapy; Estrogens; Female; Female Urogenital Diseases; | 1991 |
Continuous treatment with a combination of estrogen and gestagen--a way of avoiding endometrial stimulation. Clinical experiences with Kliogest.
Topics: Atrophy; Climacteric; Drug Combinations; Endometrium; Estradiol; Estriol; Female; Humans; Menopause; | 1985 |
[Usefulness of urethrocytologic studies in urinary incontinence].
Topics: Adult; Atrophy; Diagnosis, Differential; Epithelium; Estriol; Estrogens; Female; Humans; Male; Menop | 1985 |
[New local therapy of atrophic vaginitis].
Topics: Adult; Aged; Atrophy; Drug Combinations; Estriol; Female; Freeze Drying; Humans; Lactobacillus acido | 1972 |
[Secretion of estrone, estradiol, estriol, and epiestriol by the atrophied right gonad of the female chick embryo cultivated in vitro].
Topics: Acetates; Animals; Atrophy; Carbon Isotopes; Chick Embryo; Chromatography, Thin Layer; Culture Techn | 1969 |
[Influence of an estrogenic treatment on the skin of menopausal or castrated women].
Topics: Aged; Atrophy; Blood Circulation; Castration; Elasticity; Estriol; Female; Humans; Menopause; Middle | 1972 |
[Treatment of menopausal complants with polyoestriol-phosphate. Experiences with Gynäsan injections].
Topics: Aged; Atrophy; Biopsy; Blood Circulation; Body Temperature Regulation; Estriol; Female; Humans; Meno | 1971 |
On the effect of castration and peroral estrogen therapy on the skin.
Topics: Atrophy; Autoradiography; Castration; Estriol; Female; Humans; Mitosis; Skin; Skin Diseases; Tritium | 1971 |
[Effect of oral estrogen treatment with estriol succinate on the skin of castrated women].
Topics: Adult; Atrophy; Biopsy; Castration; Estriol; Female; Humans; Middle Aged; Skin; Skin Diseases; Succi | 1969 |
Studies on the influence of age on oestrogens in post-menopausal women with atrophic endometrium and normal liver function.
Topics: Age Factors; Aged; Aging; Atrophy; Castration; Endometrium; Estradiol; Estriol; Estrogens; Estrone; | 1969 |